The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antiphospholipid Syndrome

Antiphospholipid Syndrome

August 1, 2008 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Antiphospholipid syndrome (APS) is an autoimmune disease associated with frequent clotting in arteries and veins and fetal losses. The clotting results from the presence of proteins in the blood—called antiphospholipid autoantibodies (aPL)—formed against the person’s own tissues.

You Might Also Like
  • Antiphospholipid Antibody Syndrome
  • ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
Explore This Issue
August 2008
Also By This Author
  • How to Connect with Your Members of Congress During the August Recess

In circulation, these autoantibodies are able to interfere with some mechanisms of coagulation leading to clot formation or thrombosis (venous and/or arterial). The damage caused by this clotting can vary depending on the formation site. For instance, repeated small thrombotic events may cause heart problems (cardiac valve thickening or damage) with the risk of releasing clots into blood (arterial embolism).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Thrombosis in the arterial circulation can occur anywhere in the body, but usually happens in the brain, which can cause strokes. Patients with arterial clots can also exhibit problems in movement or vision, and repeated clots can lead to cognitive impairment.

Why patients develop these autoantibodies is not yet completely understood. Some evidence points to environmental factors, such as infections, and a genetic predisposition as playing a role in triggering the production of these autoantibodies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

APS affects women five times more often than men. It is typically diagnosed between age 30 and 40. According to patient–fact sheet author, Pier Luigi Meroni, MD, “up to 40 percent of patients with SLE will test positive for the antiphospholipid autoantibodies, and only half will develop thrombosis and/or experience fetal losses.” Like most autoimmune disorders, APS has a genetic component, although there is not a direct transmission from parent to offspring.

APS is diagnosed with a blood test for aPL given to patients with thrombosis or miscarriage. Screening is done using two kinds of assays—a clotting functional assay (the Lupus Anticoagulant test) and solid-phase assays (the anticardiolipin and the anti–b 2 glycoprotein I antibody test). Tests vary because of the differences in the aPL population. Each single test cannot detect all the possible autoantibodies, so their combined use is advised. At least one of these tests must prove positive and be confirmed in two occasions no less than three months apart to rule out transient positivity. Most often, aPL is detected after a thrombotic event or recurrent miscarriages; therefore, the main goal is prevention of recurrences, given the fact that the persistent presence of the antibodies puts the patient at strong risk for future episodes.

Acute thrombotic events (both arterial and venous) are treated as for all kinds of thromboses, independently of the presence of aPL. Typically, the blood is anticoagulated using heparin infusion into the veins, followed by oral anticoagulant drugs (e.g., coumadin). Some patients are also given compounds that dissolve clots. Subcutaneous injections of heparin and low-dose aspirin are the standard therapy for preventing new miscarriages. The therapy is started at the beginning of the pregnancy and continued in the period immediately after the delivery. This therapeutic approach has been shown to be effective in the majority of the cases, leading to the delivery of healthy babies. In nonresponsive cases, alternative therapies, such as intravenous immunoglobulin infusions, may help.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Download the complete antiphospholipid syndrome fact sheet and other patient education materials at www.rheumatology.org by following the links to patient education from the Practice Support Menu.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Education & Training, From the College Tagged With: Antiphospholipid Antibody Syndrome (APS), Autoimmune disease, Hughes Syndrome, Patient Fact SheetIssue: August 2008

You Might Also Like:
  • Antiphospholipid Antibody Syndrome
  • ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)